Explore
Featured Topics
Topics and Resources
Issues
News
Conferences
Multimedia

Videos Webinars

Subscribe Email Subscribe

Explore
Featured Topics
Topics and Resources
Issues
News
Conferences
Multimedia

Videos Webinars

Subscribe Email Subscribe

https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-opt-staging.hbrsd.com/media/350a2t1i/1126-cover.jpg

Contact Lens Spectrum

https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-opt-staging.hbrsd.com/media/zf0kqy3n/cover1.jpg

Eyecare Business

https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://pv-opt-staging.hbrsd.com/media/nabeii2w/om-novdec-2026-cover.jpg

Optometric Management

Article | AAO 2026

An Update on Phase 3 Data from DENALI

Nora Lee Cothran, OD, FAAO, sat down with OM to discuss how NCX-470, bimatoprost grenod 0.1%, performed in the US subpopulation of patients who have glaucoma.

Optometric Management November 4, 2026

Full Article
Summary
Takeaways
Listen
Scorecard
Poll

Volume

-0:00/0:00

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.